25 Biopharma Companies Raise Over RMB 6 Billion as Investment in Frontier Therapeutics Heats Up

　　【Pharmaceutical Network Industry DynamicsBy the end of 2025, the domestic biotech innovation pharmaceutical sector has seen a warming trend in financing. According to data statistics, in December 2025, the domestic biotech innovation pharmaceutical sector disclosed 25 financing events, with a total amount of approximately 6.2 billion yuan (including IPO financing of 2.277 billion Hong Kong dollars). Among these, nearly 70% were billion-yuan level financings, accounting for 17 cases.
 

From the perspective of companies that received financing in December, frontier fields such as cell and gene therapy (CGT), nucleic acid drugs, novel antibodies, and AI-driven drug discovery showed remarkable performance. In the CGT sector, multiple companies completed financing rounds in December, including HemaCell, JiDeKangMin, MengMiao Bio, JunJi Gene, Yuanma Zhiyao, and ShiAn Bio.
 

Among them, HemaCell has completed over 100 million RMB in B1 round equity financing and obtained over 100 million RMB in credit-based debt financing from multiple banks. The funds will be used to develop HemaCell's core business: the in vitro regeneration of platelet lineages, aiming to address issues such as blood supply shortages and blood-borne diseases, significantly reduce adverse consequences caused by transfusions, and develop novel drugs derived from regenerated platelets. Data shows that HemaCell is a company focused on the research and development of innovative cell therapy products. With clinical research as its foundation and cell therapy as its core technology, the company is committed to developing innovative products led by in vitro-generated platelets.
 

In the nucleic acid drug field, SANEGENEBIO announces the completion of its Series B financing. Data shows that SANEGENEBIO is an innovative enterprise focusing on small nucleic acid drug research and development. The company is committed to building an innovative small nucleic acid drug delivery platform, covering multiple research areas such as metabolism, oncology, central nervous system, immunology, ophthalmology, and rare diseases. With its cutting-edge technology and broad market prospects, SANEGENEBIO has quickly gained prominence in the biopharmaceutical field. The success of this financing will further boost SANEGENEBIO's investment in R&D, accelerating the clinical translation and industrialization process of small nucleic acid drugs. In December, Beijing Yaojing Gene Technology Co., Ltd. also received an 80-million-yuan investment. In recent years, the company has made significant progress in multiple small nucleic acid drug pipelines.
 

In recent years, the popular AI pharmaceuticals field has seen significant attention on Insilico Medicine. On December 30, Insilico Medicine successfully listed on the Hong Kong Stock Exchange. The total amount raised in this Initial Public Offering (IPO) was HKD 2.277 billion, making it the largest fundraising among Hong Kong-listed biopharmaceutical IPOs this year.
 

Data shows that Insilico Medicine has significantly improved the efficiency of new drug research and development by integrating its proprietary AI drug discovery platform with advanced automated laboratory capabilities. Compared to the traditional early-stage drug discovery process, which typically takes an average of 4.5 years, Insilico Medicine has reduced the average time from project initiation to nomination of preclinical candidate compounds (PCC) to 12-18 months across more than 20 self-developed projects between 2021 and 2024. Each project required the synthesis and testing of only 60-200 molecules. Additionally, Insilico Medicine continues to extend its expertise in AI-driven drug discovery to address more unmet disease areas. Focusing on key therapeutic areas such as fibrosis, oncology, immunology, inflammation, cardiometabolic disorders, and central nervous system diseases, the company has built a pipeline portfolio comprising over 30 projects with a clear gradient. Ten projects have received clinical trial approvals, seven of which are actively advancing in clinical studies.
 

Moreover, in the antibody drug sector, companies such as Deshengji Pharmaceuticals, Kangyuan Bochuang, and Anlilu Biotechnology successively secured substantial financing in December, demonstrating continued capital confidence in the innovative value of this field.
 

The financing warmth at the end of 2025 has injected strong momentum into China's biotech innovation pharmaceutical industry. With continuous breakthroughs in cutting-edge technologies and the advancement of excellent pipelines, under the rational support of capital, China's biotech innovation pharmaceutical industry is expected to accelerate towards a new stage of high-quality development, laying a solid foundation for addressing unmet clinical needs and enhancing global competitiveness.
 

Disclaimer: In no case shall the information or opinions expressed in this article constitute investment advice to any person.